Myeloproliferative Disorder, Aquagenic Pruritus
Conditions
Brief summary
Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.
Detailed description
Identification of patients with myeloproliferative neoplasms and aquagenic pruritus. Evaluation of the intensity of the aquagenic pruritus. Patients with value \>5/10 on the VAS (Visual Analogue Scale ) are proposed to participate to the protocole. Randomization between the two treatments. Duration of the treatment : 14 days. Regular evaluation of efficacity of the drugs (questionnaires). Evaluations will stop 2 months after the last intake. Blood samples will be collected before and after the intakes to study cytokine and neuropeptide levels.
Interventions
DRUGAprepitant 80 mg
oral therapy - daily dose - 14 days
DRUGHydroxyzine 25mg
oral therapy - daily dose - 14 days
DRUGPlacebo of Hydroxyzine
oral therapy - daily dose - 14 days
oral therapy - daily dose - 14 days
Sponsors
University Hospital, Brest
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Intervention model description
Phase 3, randomized prospective study, double blind-double placebo
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Major patients with myeloproliferative neoplasms (polycythemia vera, essential thrombocythaemia or myelofibrosis) * and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon, ruxolitinib or bled for more than 6 months * and suffering of persistent aquagenic pruritus * and with a pruritus intensity on Analogic Visual Scale \>5/10 * patients who gave their written consent for participation in the study
Exclusion criteria
* patients with a physical or psychological disability to sign the consent form * patients with myeloproliferative neoplasms and suffering of aquagenic pruritus but only treated by aspirin * patients already included in another therapeutic protocol * patients with diffuse dermatological disease where pruritus may be present (psoriasis, atopic dermatitis, prurigo * patients already on anti-anxiety and / or anti-depressant treatment * patients with absolute contraindications to the use of Aprepitant or Hydroxyzine * hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients * lactose intolerance * pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale ) | at 15 days | number of patients with a pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cessation of pruritus | at 15 days | number of patients with a pruritus intensity at 0/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms) ) |
| Time observed to decreased the VAS to 3/10 | 01 to 60 days | number of days to obtain an intensity of pruritus at 3/10 on the VAS (Visual Analogue Scale ) |
| Duration of treatment effectiveness | 1 to 60 days | number of days the VAS (Visual Analogue Scale ) is below (or equal) 3/10 |
| Adverse event occurring during the association therapeutic | at 15 days | type of adverse event occuring during the treatment period |
| Number of prematurely discontinued anti-pruritic treatment | at 15 days | Total number of prematurely discontinued treatments for all subjects |
| Reduction of pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale ) | at 60 days | number of patients with a pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms) |
| Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire | at J0 (day of inclusion) | Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire |
| Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire | at J0 (day of inclusion) | Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire |
| Quality of life through the use of validated questionnaires : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire | at 30 days | Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire |
| Quantification of the change of plasma concentrations of cytokines and neuropeptides | at J0 (day of inclusion) | Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL) |
| Complete blood count (normal or abnormal) | 1 to 60 days | number of patients with hematologic remission : hematocrit \<45% with leukocytes \<10 giga/l and platelets \<400 giga/l |
Countries
France
Outcome results
None listed